TY - JOUR
T1 - Detection and evaluation of signals associated with exposure to individual and combination of medications in pregnancy: A signal detection study protocol
AU - Subramanian, Anuradhaa
AU - Lee, Siang Ing
AU - Hemali Sudasinghe, Sudasing Pathirannehelage Buddhika
AU - Wambua, Steven
AU - Phillips, Katherine
AU - Singh, Megha
AU - Azcoaga-Lorenzo, Amaya
AU - Cockburn, Neil
AU - Wang, Jingyan
AU - Fagbamigbe, Adeniyi Francis
AU - Usman, Muhammad
AU - Damase-Michel, Christine
AU - Yau, Christopher
AU - Kent, Lisa
AU - McCowan, Colin
AU - OâReilly, Dermot
AU - SANTORELLI, Gillian
AU - Hope, Holly
AU - Kennedy, Jonathan I.
AU - Mhereeg, Mohamed
AU - Abel, Kathryn M
AU - Eastwood, Kelly-Ann
AU - Black, Mairead
AU - Loane, Maria
AU - Moss, Ngawai
AU - Brophy, Sinead
AU - Brocklehurst, Peter
AU - Dolk, Helen
AU - Nelson-Piercy , Catherine
AU - Nirantharakumar, Krishnarajah
N1 - © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
Publisher Copyright:
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.
PY - 2023/10/9
Y1 - 2023/10/9
N2 - INTRODUCTION: Considering the high prevalence of polypharmacy in pregnant women and the knowledge gap in the risk-benefit safety profile of their often-complex treatment plan, more research is needed to optimise prescribing. In this study, we aim to detect adverse and protective effect signals of exposure to individual and pairwise combinations of medications during pregnancy. METHODS AND ANALYSIS: Using a range of real-world data sources from the UK, we aim to conduct a pharmacovigilance study to assess the safety of medications prescribed during the preconception period (3 months prior to conception) and first trimester of pregnancy. Women aged between 15 and 49 years with a record of pregnancy within the Clinical Practice Research Datalink (CPRD) Pregnancy Register, the Welsh Secure Anonymised Information Linkage (SAIL), the Scottish Morbidity Record (SMR) data sets and the Northern Ireland Maternity System (NIMATS) will be included. A series of case control studies will be conducted to estimate measures of disproportionality, detecting signals of association between a range of pregnancy outcomes and exposure to individual and combinations of medications. A multidisciplinary expert team will be invited to a signal detection workshop. By employing a structured framework, signals will be transparently assessed by each member of the team using a questionnaire appraising the signals on aspects of temporality, selection, time and measurement-related biases and confounding by underlying disease or comedications. Through group discussion, the expert team will reach consensus on each of the medication exposure-outcome signal, thereby excluding spurious signals, leaving signals suggestive of causal associations for further evaluation. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Independent Scientific Advisory Committee, SAIL Information Governance Review Panel, University of St. Andrews Teaching and Research Ethics Committee and Office for Research Ethics Committees Northern Ireland (ORECNI) for access and use of CPRD, SAIL, SMR and NIMATS data, respectively.
AB - INTRODUCTION: Considering the high prevalence of polypharmacy in pregnant women and the knowledge gap in the risk-benefit safety profile of their often-complex treatment plan, more research is needed to optimise prescribing. In this study, we aim to detect adverse and protective effect signals of exposure to individual and pairwise combinations of medications during pregnancy. METHODS AND ANALYSIS: Using a range of real-world data sources from the UK, we aim to conduct a pharmacovigilance study to assess the safety of medications prescribed during the preconception period (3 months prior to conception) and first trimester of pregnancy. Women aged between 15 and 49 years with a record of pregnancy within the Clinical Practice Research Datalink (CPRD) Pregnancy Register, the Welsh Secure Anonymised Information Linkage (SAIL), the Scottish Morbidity Record (SMR) data sets and the Northern Ireland Maternity System (NIMATS) will be included. A series of case control studies will be conducted to estimate measures of disproportionality, detecting signals of association between a range of pregnancy outcomes and exposure to individual and combinations of medications. A multidisciplinary expert team will be invited to a signal detection workshop. By employing a structured framework, signals will be transparently assessed by each member of the team using a questionnaire appraising the signals on aspects of temporality, selection, time and measurement-related biases and confounding by underlying disease or comedications. Through group discussion, the expert team will reach consensus on each of the medication exposure-outcome signal, thereby excluding spurious signals, leaving signals suggestive of causal associations for further evaluation. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Independent Scientific Advisory Committee, SAIL Information Governance Review Panel, University of St. Andrews Teaching and Research Ethics Committee and Office for Research Ethics Committees Northern Ireland (ORECNI) for access and use of CPRD, SAIL, SMR and NIMATS data, respectively.
KW - epidemiology
KW - maternal medicine
KW - obstetrics
UR - http://www.scopus.com/inward/record.url?scp=85175660329&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2023-073162
DO - 10.1136/bmjopen-2023-073162
M3 - Article
C2 - 37813531
SN - 2044-6055
VL - 13
SP - 1
EP - 11
JO - BMJ Open
JF - BMJ Open
IS - 10
M1 - e073162
ER -